Multiple Myeloma Patients
Related entities
Findings (27)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)
None
declineMultiple myeloma patients with higher pre-diagnosis insulinemic dietary scores had 16-17% higher MM-specific mortality per 1-SD increase, suggesting that diets promoting insulin resistance or hyperins
Effect: decline; HR 1.16 (EDIR); HR 1.17 (EDIH); CI: 95% CI 1.02 to 1.33 (EDIR); 95% CI 1.01 to 1.35 (EDIH)